Literature DB >> 1969642

Beta-blockers and central nervous system side effects.

J McAinsh1, J M Cruickshank.   

Abstract

Beta-adrenergic blocking drugs are a widely used, well tolerated and effective treatment for a variety of cardiovascular and noncardiovascular disorders. Over the years, beta-blockers have been associated with an incidence, albeit low, of CNS side effects. The question of interest, however, is whether the incidence is the same for all members of the class or whether other properties, such as hydrophilicity, have a bearing on the incidence of this type of side effect? This article addresses this question. In pharmacokinetic terms the lipophilic beta-blockers have been shown, both in animals and man, to readily cross the blood-brain barrier in contrast to hydrophilic beta-blockers. This is thought to have possible clinical relevance with respect to the relative incidence of CNS side-effects. To clarify the situation every published clinical paper, in which the beta-blockers propranolol (highly lipophilic, nonselective, no intrinsic sympathomimetic activity (ISA)), pindolol (moderately lipophilic, nonselective, moderate ISA), metoprolol (moderately lipophilic, beta 1-selective, no ISA) and atenolol (hydrophilic beta 1-selective, no ISA) were compared, was assessed for information pertaining to CNS side effects. This comprehensive review of the literature has shown, with few exceptions, that the incidence of CNS side effects such as sleep disturbances, dreaming, nightmares and hallucinations following clinically accepted doses of the four beta-blockers under scrutiny is generally low and that effects on short-term memory are minimal or absent. However, within this group of four drugs the incidence of these side effects is lowest with hydrophilic atenolol and generally highest with pindolol and propranolol. Metoprolol occupies an intermediate position. This order is in agreement with the pharmacokinetic observation that the more hydrophilic the molecule, the less is found in the brain tissue of both animals and man, although in the case of pindolol other factors may be important. The clinical relevance of studies involving psychometric testing is not clear.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969642     DOI: 10.1016/0163-7258(90)90092-g

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  34 in total

1.  {Beta}-blocker drugs mediate calcium signaling in native central nervous system neurons by {beta}-arrestin-biased agonism.

Authors:  Anastassios V Tzingounis; Mark von Zastrow; Guillermo A Yudowski
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  Protective effect of propranolol and nadolol on social defeat-induced behavioral impairments in rats.

Authors:  Safiyya Zaidi; Fatin Atrooz; Daniel Valdez; Hesong Liu; Camila Kochi; Richard A Bond; Samina Salim
Journal:  Neurosci Lett       Date:  2020-03-09       Impact factor: 3.046

Review 3.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

4.  Ivabradine and nightmares: a previously unreported adverse reaction.

Authors:  Knut Tore Lappegård; Elisabet Nordmo
Journal:  Eur J Clin Pharmacol       Date:  2011-06-24       Impact factor: 2.953

Review 5.  Possible indications of beta-blockers in the perioperative period other than prevention of cardiac ischemia.

Authors:  Yuji Kadoi; Shigeru Saito
Journal:  J Anesth       Date:  2010-02       Impact factor: 2.078

Review 6.  Risk of insomnia with non-vitamin K oral anticoagulants: systematic review and meta-analysis.

Authors:  Daniel Caldeira; Márcio Barra; Ana Teresa Santos; Daisy de Abreu; João Costa; Joaquim J Ferreira
Journal:  Sleep Breath       Date:  2015-01-27       Impact factor: 2.816

7.  Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis.

Authors:  Annelies C Ham; Suzanne C van Dijk; Karin M A Swart; Anke W Enneman; Nikita L van der Zwaluw; Elske M Brouwer-Brolsma; Natasja M van Schoor; M Carola Zillikens; Paul Lips; Lisette C P G M de Groot; Albert Hofman; Renger F Witkamp; André G Uitterlinden; Bruno H Stricker; Nathalie van der Velde
Journal:  Br J Clin Pharmacol       Date:  2017-07-04       Impact factor: 4.335

Review 8.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

Review 9.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve.

Authors:  P G Davey; M Charter; S Kelly; T R Varma; I Jacobson; A Freeman; E Precious; J Lambert
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.